

SCIENTIFIC PROGRAMME

4th Congress “Malignancy in young adults”

FRIDAY, NOVEMBER 27, 2026

11:30–12:00 | Registration and Welcome

12:00–13:30 | Clinical Trials

Chairs: K. Poulimenos, K. Ntziamaras, Z. Varsami

- Good Clinical Practice (GCP): From Theory to Practice
F. Kiospe
- Management of Adverse Events in Clinical Trials
S. Sourmeli
- Recruitment and Retention: Increasing Participation in Clinical Trials
A. Maneta
- Inspection Readiness: Preparing a Clinical Research Site
N. Tourkogiorgos
- The Patient and the Clinical Trial: From Informed Consent to Randomization
S. Asimakopoulou
- Presentation of Clinical Trials at the Oncology Unit of Aretaieion Hospital
A. Sofianidi

Discussion: S. Verarou, A. Papakosta, A. Niarchou

13:30–15:00 | Cancer and Pregnancy

Chairs: Em. Kalampokas, E. Lianos, A. Safarika

- Is There an Increased Risk of Malignancy in Young Women Following IVF or Fertility Drug Treatment?
Th. Sergentanis
- Cervical Cancer and Other Gynecological Malignancies During Pregnancy
E. Panagomidou
- Fertility Preservation in Women with Gynecological Malignancies
Th. Kalampokas

- Gestational Trophoblastic Disease: Latest Evidence
E. Skafida

Discussion: Th. Panoskaltsis, A. Tsigginou, M. Oikonomou

15:00–16:00 | Gynecological Cancer

Chairs: M. A. Dimopoulos, D. Myoteri, N. Vlachos

- Genetic Testing in Patients with Endometrial and Cervical Cancer: Who Should Be Tested and How Can the Results Guide Treatment?
V. Spiliopoulou
- Latest Evidence on First-Line Treatment of Advanced Endometrial Cancer: The Role of Novel Therapies in Younger Patients
M. Skondra
- Latest Evidence in Platinum-Resistant Ovarian Cancer: The Role of Novel Therapies in Younger Patients
M. Kaparellou

Discussion: Aik. Deliveliotou-Toutouza, N. Thomakos, K. Goula

16:00–16:30 | Innovative Therapies in Oncology

Chairs: A. Psyrri, E. Goga, Ath. Kotsakis

- CAR T Cells and CRISPR: A New Era in Cell and Gene Therapies
I. Danasis-Stathopoulos
- Personalized Anticancer mRNA Vaccines: The Next Era of Immunotherapy
M. Lontos

Discussion: G. Bletsas, E. Galani, N. Kapodistrias

16:30–17:00 | Coffee Break

17:00–18:00 | New Technologies – The Oncology of Tomorrow

Chairs: G. Fountzilas, E. Kastritis, M. Nikolaou

- Liquid Biopsy in Oncology: ctDNA, CTCs, and MRD in Therapeutic Decision-Making
P. Malandrakis
- Artificial Intelligence in Oncology: Response Prediction and Treatment Individualization
E. Zografou
- Genomics in Clinical Oncology: NGS, Germline and Somatic Mutations in the Era of Personalized Medicine
E. Kounadi
- Organoids and Organ-on-a-Chip: Towards Truly Personalized Oncology
A. Dimitriou

Discussion: C. Christodoulou, A. Koumarianou, R. Krasteva

18:00–18:45 | Colorectal Cancer

Chairs: Th. Theodosopoulos, N. Tiniakou, Z. Saridaki

- Metastasectomy in Young Patients with Stage IV Colorectal Cancer: The Role of the Surgeon in the Era of Liquid Biopsy
K. Zografos
- Perioperative Systemic Therapy and Immunotherapy in Early-Stage Colon Cancer: New Evidence and Future Perspectives
A. Papatheodoridi
- BRAF Mutations in Metastatic Colorectal Cancer
V. Michalaki

Discussion: I. Papakonstantinou, K. Toutouzas, M. Theochari

18:45–19:30 | Pancreatic Cancer

Chairs: M. Konstantoulakis, A. Vezakis, P. Markantonakis

- Latest Evidence on Neoadjuvant Treatment of Pancreatic Cancer
K. Aravantinou-Fatorou
- Latest Evidence in Metastatic Pancreatic Cancer
K. Perdikari

Discussion: G. Papatheodoridis, K. Bramis, S. Peroukidis

19:30–20:00 | Opening Ceremony

20:00–20:30 | KEY LECTURE

Chairs: F. Zagouri, M. Konstantoulakis

- The Ability of Healthcare Systems to Accommodate Advances in Pharmaceutical Innovation
Ath. Zamanis
-

SATURDAY, NOVEMBER 28, 2026

09:00–10:30 | Student Round Table: Young People and Modern Lifestyles

Chairs: G. K. Zografos, Ev. Oikonomou, D. Chrysikos

- Smoking and Vaping at a Young Age: What Do We Know About the Risk of Developing Cancer?
E. Konstantoulaki
- Diet and Obesity: The Impact of Modern Dietary Habits
S. Dimopoulou
- Alcohol and Cancer: Which Malignancies Are Associated with Alcohol Consumption?
I. Tataris
- Exercise as a Shield Against Cancer: From Biology to Prevention
F. Pantou
- Microplastics and Environmental Exposure: Is There a Real Cancer Risk?
M. R. Koutrouli

10:30–11:30 | Adjuvant Therapy in Breast Cancer (I)

Chairs: G. Xepapadakis, A. Koutras, F. Poulakaki

- Breast Cancer in Young Patients: A Distinct Biological Entity? Epidemiological and Molecular Evidence
E. Panopoulou
- ctDNA and Liquid Biopsy: Do They Have a Role in Monitoring High-Risk Patients?
A. Svarna
- Fertility and Pregnancy After Breast Cancer: Latest Evidence
V. Stafylla
- The SERD Revolution: Redefining Endocrine Therapy
I. Kollarou

Discussion: S. Marinopoulos, P. Kontogianni, P. Ntasiou

11:30–12:00 | Coffee Break

12:00–13:00 | Adjuvant Therapy in Breast Cancer (II)

Chairs: N. Arkadopoulos, D. Tryfonopoulos, M. Tolia

- HER2-Positive Early Breast Cancer in Young Patients: Post-Neoadjuvant Strategies
D. Stefanou
- Triple-Negative Breast Cancer in Young Patients: Post-Neoadjuvant Strategies and the Role of Antibody–Drug Conjugates (ADCs)
A. Andrikopoulou
- De-escalation of Adjuvant Treatment in Young Patients: Latest Evidence
A. M. Papanota
- De-escalation of Radiotherapy in Early-Stage Disease
E. Vasilakou

Discussion: S. Karageorgopoulou, I. Flessas, A. Giannos

13:00–14:30 | Metastatic Breast Cancer

Chairs: K. Dimitrakakis, E. Timotheadou, G. Kafiri

- HR-Positive/HER2-Negative Metastatic Breast Cancer: What Comes After CDK4/6 Inhibitors?
E. Aravantinou-Fatorou
- Latest Evidence in HER2-Positive Metastatic Breast Cancer in Younger Patients
M. Anastasiou
- Latest Evidence in Triple-Negative Breast Cancer in Younger Patients: The Role of Antibody–Drug Conjugates (ADCs)
Ch. Markellos
- Surgical Management of Oligometastatic Disease
S. Lanitis

Discussion: V. Milionis, L. Papadopoulos, P. Grigoropoulos

14:30–15:30 | Lunch Break

15:30–16:30 | Lung Cancer

Chairs: S. Angelaki, M. Gavriatopoulou, S. Baka

- Epidemiological Data on Lung Cancer in Younger Age Groups
S. Spyropoulou
- Immunotherapy and Targeted Therapy in the Adjuvant Treatment of Non-Small Cell Lung Cancer (NSCLC)
K. Ch. Perdikari
- Targeted Therapies in Metastatic NSCLC
A. Kosma
- Emerging Therapies in Small Cell Lung Cancer (SCLC): ADCs and DLL3
E. A. Makrantonakis

Discussion: P. Katsaounos, K. Vasilikos, A. Zetos

16:30–17:30 | Genitourinary Cancer

Chairs: A. Bamias, A. Zygogianni, A. Dellis

- Which Patients with Prostate Cancer Should Undergo Genetic Testing, and How Can the Results Guide Treatment?
K. Koutsoukos
- Latest Evidence on Adjuvant Therapy in Young Patients with Renal Cell Carcinoma
R. Zakopoulou
- Testicular Cancer: Acute and Chronic Complications of Systemic Therapy
A. Michas
- Stereotactic Body Radiotherapy (SBRT) in Renal Cell Carcinoma
P. Skarlos

Discussion: G. Samelis, M. Migkou, A. Ploumidis

17:30–18:30 | Sarcomas in Children and Young Adults – CNS Tumors

Chairs: V. Kouloulas, A. Kyriazoglou, V. Barbounis

- Modern Histopathological Diagnosis: From Morphology to Immunohistochemistry and Molecular Pathology
G. Agrogiannis
- Surgical Management of Soft Tissue Sarcomas
N. Memos
- Soft Tissue Sarcomas: Latest Evidence
St. Kokkali
- Glioblastoma: Latest Evidence
D. Kalapanida

Discussion: A. Boutis, I. Georgakopoulos, K. Barkas

18:30–19:00 | Conclusions and Closing Ceremony